Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pathway Study: HuCNS-SC in Cervical Spinal Cord Injury
NCT02163876Phase 2Terminated
- Sponsor
- StemCells, Inc.
- Start
- Oct 2014
- Primary completion
- May 2016
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of HuCNS-SC in cervical spinal cord injury (2 arms), sponsored by StemCells, Inc. Primary endpoint: International Standards for Neurological Classification of Spinal Cord Injury Upper Extremity Motor Score at 1 year. Started Oct 2014; status: terminated.
02
Drugs
HuCNS-SC
03
Conditions
cervical spinal cord injury
Beyond the preview
Go deeper on NCT02163876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163876.